FAQ: Cybin Inc. Annual Meeting Voting Results and Company Overview

What is the main topic of this announcement?

This announcement covers the voting results from Cybin Inc.’s annual meeting of shareholders held on August 18, 2025, and provides an overview of the company’s clinical development programs in neuropsychiatry.

When was Cybin’s annual shareholder meeting held?

The annual meeting of shareholders was held on August 18, 2025.

What percentage of Cybin’s outstanding shares were represented at the meeting?

A total of 48.92% of the company’s issued and outstanding common shares were represented at the meeting through 90 shareholders present in person or by proxy.

What type of company is Cybin Inc.?

Cybin is a clinical-stage neuropsychiatry company developing next-generation mental healthcare treatments for various mental health conditions.

What are Cybin’s main drug development programs?

Cybin is developing CYB003, a deuterated psilocin analog in Phase 3 studies for major depressive disorder, and CYB004, a deuterated N,N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder.

Where is Cybin operational?

Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

When was Cybin founded?

Cybin was founded in 2019.

Where can investors find the latest news and updates about Cybin?

The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.

What is the significance of Cybin’s approach to mental health treatment?

Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long-lasting results, addressing the large unmet need for people suffering from mental health conditions.

How many common shares were represented at the annual meeting?

A total of 11,264,212 common shares were represented at the annual meeting, held by 90 shareholders either in person or by proxy.